BPC-157 and TB-500: What the Research Shows

Most of the published work cited for the BPC 157 TB 500 pairing was never a combination study. BPC-157 and TB-500 occupy two largely separate bodies of literature, produced by different research groups, in different model systems, across different decades. The notion that the two function as a single synergistic repair system is a convention of online protocol writing rather than a conclusion drawn from a controlled experiment testing each compound alone and together.

The BPC-157 record is dominated by one long running research program. Sikiric and colleagues summarised that program in Current Pharmaceutical Design in 2011 (PMID 21548867), describing the stable gastric pentadecapeptide across gastrointestinal and vascular rodent models. The TB-500 record traces back to thymosin beta-4, a 43 amino acid actin sequestering protein reviewed by Goldstein and colleagues in Expert Opinion on Biological Therapy in 2012 (PMID 22074294). The two literatures rarely cite one another.

'What are BPC 157 TB 500 peptides in research?'

BPC 157 TB 500 refers to two research peptides studied for tissue repair signalling: BPC-157, a 15 amino acid pentadecapeptide with a molecular weight near 1419 Da, and TB-500, a synthetic peptide related to the 43 amino acid protein thymosin beta-4. The published evidence is almost entirely preclinical. Verifying molecular identity before procurement matters more than study design.

The common oversimplification is that the two compounds do the same thing by the same route. The literature describes different primary mechanisms: BPC-157 is associated with angiogenic signalling and growth factor receptor expression in connective tissue cells, while thymosin beta-4 acts first on the actin cytoskeleton and on cell migration. Anyone searching BPC 157 TB 500 is usually looking for a comparison that the forums never provide. This page covers the molecular identity of each compound, the mechanisms reported in peer reviewed models, the depth of human research behind each, the identity checks that separate correctly labelled material from mislabelled material, and the current regulatory and anti-doping position.

What exactly are these two peptides at the molecular level?

BPC-157 is a pentadecapeptide, meaning a chain of exactly 15 amino acids, with the sequence GEPPPGKPADDAGLV. It corresponds to a partial sequence of body protection compound, a protein isolated from human gastric juice. Its CAS registry number is 137525-51-0 and its free base molecular weight is approximately 1419.5 Da, though most laboratory material is supplied as an acetate salt, which shifts the measured mass on a certificate. Sikiric and colleagues (2011) describe the molecule as stable in human gastric juice for more than 24 hours, a property that is unusual among short peptides and that explains why so much of the early work used oral model systems. Background on sequence, synthesis and model coverage sits on the BPC-157 compound hub.

TB-500 is a trade name rather than a precise chemical designation, which is the root of most confusion in catalog listings for BPC 157 TB 500 material. Thymosin beta-4 carries CAS number 77591-33-4, runs to 43 amino acids, and has a molecular weight near 4963 Da. It is one of the most abundant intracellular proteins in many mammalian cell types and binds monomeric G-actin through a short motif, LKKTETQ, sitting at residues 17 to 23. Strictly, TB-500 was introduced as a synthetic construct built around that actin binding region. In practice the name is applied loosely to both the fragment and to full length thymosin beta-4, which is why molecular weight on a lot certificate is the only reliable discriminator. The TB-500 compound overview sets out the sequence question in more detail, and a side by side explainer covering how GHK-Cu, TB-500, BPC-157 and KPV differ is useful for researchers mapping an entire repair focused panel rather than a single compound.

How does BPC-157 behave in published preclinical models?

The most frequently cited mechanistic work on BPC-157 is in connective tissue cells. Chang and colleagues (2011), publishing in the Journal of Applied Physiology, reported that the pentadecapeptide increased outgrowth from cultured rat Achilles tendon explants, promoted tendon fibroblast migration, and was associated with phosphorylation of focal adhesion kinase and paxillin, two proteins that govern how a cell attaches to and crawls across its matrix. The same group reported in Molecules in 2014 that BPC-157 upregulated growth hormone receptor expression in tendon fibroblasts, which offers a plausible route by which a local peptide signal could amplify a systemic growth signal already present in tissue.

The second mechanistic thread in the BPC 157 TB 500 literature is vascular. Reviews by Sikiric and by Seiwerth and colleagues (2021, Frontiers in Pharmacology) describe interaction with the nitric oxide system and with vascular endothelial growth factor receptor signalling, framing the compound as cytoprotective and angiogenic rather than anabolic. Gwyer, Wragg and Wilson (2019) reviewed the musculoskeletal soft tissue evidence in Cell Tissue Res and concluded that the preclinical signal is consistent across tendon, ligament and muscle injury models while noting the near total absence of human data.

Model specificity is the caveat that gets lost in summary. Results generated in a transected rat tendon do not transfer automatically to a degenerative or compressive condition, which is why question led research pages such as what the studies report on BPC-157 and meniscus injury, BPC-157 and iliotibial band syndrome research and the evidence around spinal disc models exist as separate discussions. The gastrointestinal literature is older and larger than the musculoskeletal literature, and the mechanistic data on gastric and oesophageal models remains the best characterised part of the record.

What does thymosin beta-4 actually do, and is TB-500 the same molecule?

Thymosin beta-4 is first and foremost an actin sequestering protein. By binding monomeric actin it controls the pool available for filament assembly, and that single function sits upstream of cell migration, cytoskeletal remodelling and barrier repair. Malinda and colleagues (1999) reported in the Journal of Investigative Dermatology that thymosin beta-4 accelerated wound repair in rodent dermal models, with increased keratinocyte migration and collagen deposition. Bock-Marquette and colleagues (2004) reported in Nature that thymosin beta-4 activated integrin linked kinase and Akt signalling, promoting cardiac cell migration and survival in a mouse coronary ligation model. Goldstein and colleagues (2012) later catalogued the breadth of that activity across dermal, corneal and cardiac systems.

Here is the point most BPC 157 TB 500 discussions skip entirely. Almost every peer reviewed paper cited in support of TB-500 was generated using full length thymosin beta-4, not an abbreviated synthetic fragment. A researcher who cites Bock-Marquette 2004 to justify a TB-500 experiment is citing data from a 43 residue protein. If the vial in the freezer contains a short actin binding fragment instead, the citation does not support the experiment, and any null result will be impossible to interpret. Molecular weight and the mass spectrometry trace on the lot certificate resolve the question in under a minute, and nothing else does. Appearance, solubility and label text do not.

That identity problem also explains why reported timelines vary so widely between sources. Summaries of how long TB-500 took to show effects in published models and of what the literature reports on TB-500 in muscle recovery research describe different model systems using the same trade name, which makes cross study comparison unreliable unless the exact molecule used in each experiment is confirmed.

Why are the two compounds studied together, and what does that assume?

The stated rationale for pairing is mechanistic complementarity. BPC-157 is described in the literature as acting on vascular signalling and on growth factor receptor expression within resident connective tissue cells, while thymosin beta-4 acts on the actin cytoskeleton and on the migration of cells into a wound bed. On paper, one compound would support new vessel formation and local signalling while the other supports cell movement, and the combination would address two sequential requirements of tissue repair rather than one.

The BPC 157 TB 500 pairing assumes something the published record does not establish. A genuine synergy claim requires a factorial design: compound A alone, compound B alone, both together, and vehicle control, measured against the same endpoint in the same model. Searches of the indexed literature return no such published trial. What exists is two parallel sets of single compound studies, often in different species, different injury models and different laboratories, with different endpoints. Combining their conclusions is an inference, not a finding, and inference of that kind is how preclinical programs waste a year.

For research planning, that gap is an opportunity rather than a dead end, because a properly controlled combination study in a single model would be genuinely novel. Researchers assembling a panel of repair focused compounds often work from a muscle growth and recovery research category and from sourcing notes covering GHK-Cu, TB-500, BPC-157 and KPV together, since a factorial design needs every arm sourced from verified material with matching lot documentation. Related discussion of what the literature reports on BPC-157 in injury prevention contexts covers the prophylactic model designs that sit outside the standard wound repair framework.

How much human evidence exists behind either compound?

Very little, and the asymmetry between the two is significant. BPC-157 has no completed large scale randomised controlled trial published in the indexed literature. Reviews by Sikiric and by Seiwerth reference early phase human work in inflammatory bowel conditions, but the compound has not progressed to a published pivotal trial, and it has not been approved by the FDA as a drug product for any indication. Every mechanistic claim in general circulation traces to rodent or cell culture work.

Thymosin beta-4 has travelled further. Formulations of the full length protein have been entered into registered clinical trials for ophthalmic surface conditions and for dermal repair indications, which places it in a different regulatory category of evidence maturity even though no approval has followed. That distinction matters when weighing the human evidence behind BPC 157 TB 500 claims: the two compounds are not equally supported, and the better supported half of the pair is the one most often mislabelled.

The practical consequence is that secondary claims circulating about either compound sit even further from the data than the primary repair claims do. Questions such as what the literature reports on BPC-157 and immune signalling, whether any published work addresses BPC-157 and lipid markers, or what models exist for BPC-157 in intestinal inflammation research each rest on a narrower slice of preclinical evidence than the tendon and gastric literature does. Research planning should weight those claims accordingly, and should treat any source that presents rodent findings as settled human outcomes as unreliable on its face.

BPC 157 TB 500 compared side by side: where do the two differ?

The table below compares the two compounds on the attributes that change how a study is designed and how material is sourced. It is built from the molecular identity data and the peer reviewed findings cited above rather than from marketing summaries, and the BPC 157 TB 500 contrast is sharpest on identity verification and on depth of human research.

Key takeaways: what does the current evidence actually support?

• BPC-157 is a 15 amino acid pentadecapeptide with a free base mass near 1419.5 Da, while thymosin beta-4 is a 43 amino acid protein near 4963 Da, so the two differ by more than threefold in size and cannot be treated as interchangeable repair agents.
• No published factorial study tests BPC 157 TB 500 together against each compound alone, which means every synergy claim in circulation is inference rather than finding.
• The strongest mechanistic data for BPC-157 comes from tendon fibroblast work by Chang and colleagues in 2011 and 2014, reporting increased cell migration, focal adhesion kinase phosphorylation and growth hormone receptor upregulation.
• The strongest mechanistic data behind the TB-500 name was generated with full length thymosin beta-4, including Malinda 1999 in dermal repair models and Bock-Marquette 2004 in a murine cardiac model.
• Thymosin beta-4 has entered registered human clinical trials for ophthalmic and dermal indications, while BPC-157 has no completed published pivotal trial.
• Molecular weight and mass spectrometry data on a lot specific certificate of analysis are the only reliable way to confirm which molecule a TB-500 labelled vial contains.

What do researchers ask when the material or the data does not line up?

Five recurring situations account for most of the confusion around BPC 157 TB 500 research planning, and each has a procedural answer rather than a judgement call.

What if a protocol cites TB-500 but the source paper used full length thymosin beta-4?

The citation should be rewritten or the material should be changed so that molecule and reference match. Chain length determines whether the full actin binding and signalling repertoire described by Goldstein and colleagues in 2012 is present, or whether only a short motif is. A study that pairs a fragment with full length protein citations cannot interpret a negative result, because failure of the compound and failure of the premise look identical in the data.

What if a lyophilised vial was left outside controlled storage?

The lot should be treated as compromised for quantitative work until stability can be confirmed. Peptide degradation is not visible to the eye, and partial hydrolysis lowers the effective amount of intact molecule without changing the appearance of the powder. A dedicated discussion of what happens when BPC-157 leaves cold storage covers the stability questions that apply to lyophilised short peptides generally.

What if the certificate of analysis came from the seller rather than an independent laboratory?

It should be treated as an unverified document. An in house certificate confirms what a supplier states about its own material, which is a different claim from an independent third party confirming identity by mass spectrometry and chromatographic separation. Guidance on distinguishing correctly identified BPC-157 material from mislabelled material sets out the specific document fields that matter, starting with lot number, test date and testing laboratory.

What if a comparison against another repair focused peptide is needed?

The comparison should be restricted to compounds with overlapping model systems, otherwise the exercise compares literatures rather than molecules. Published contrasts such as ARA-290 against BPC-157 and Cartalax against BPC-157 are useful precisely because they identify where the evidence bases do not overlap, which is often the most informative part of the answer.

What if one model reports a large effect and another reports nothing?

The first variable to check is injury type, not compound quality. Transection, ischaemia, chemical lesion and degenerative models recruit different repair pathways, and a compound acting on angiogenic signalling will register strongly in a model limited by perfusion and weakly in one limited by mechanical load. Species, strain, endpoint timing and assay sensitivity account for most apparent contradictions in the preclinical record.

Is the combined approach as well supported as it sounds?

The honest reading of the literature is this: the combination is a convention, not a conclusion. Two separate preclinical evidence bases have been stitched together by repetition, and the stitching has never been tested. BPC-157 has strong, internally consistent rodent data and almost no human data. The molecule behind most TB-500 citations has reached human trials but is frequently not the molecule being sold under that name. Those are two different problems, and buying both compounds does not solve either. The most valuable work available in this space is a properly controlled combination study that nobody has published yet.

How can a laboratory confirm what is actually in the vial?

Four checks answer the question, and they run in order. First, match the CAS number on the documentation against the compound named on the label: 137525-51-0 for BPC-157 and 77591-33-4 for thymosin beta-4. Second, read the observed mass on the mass spectrometry report against the expected mass for the stated sequence and salt form, remembering that acetate salt presentation shifts the number upward. Third, examine the chromatographic trace for a single dominant peak with a clean baseline rather than relying on a summary figure. Fourth, confirm the testing laboratory named on the certificate is independent of the supplier and that the document carries a lot number matching the vial in hand.

Real Peptides supplies research use only compounds and publishes lot specific certificates of analysis from independent third party testing, which can be matched against individual lot numbers in the published certificate of analysis library. That documentation is what allows a result to be defended later, because a reviewer asking what was in the vial expects a lot number and a traceable report, not a product description.

All compounds discussed on this page are sold for laboratory research use only and are not for human consumption. The designation is a legal classification governing supply and labelling rather than a formality, and an explainer on what research use only actually means covers how that status constrains what any supplier may state about a compound.

What is the regulatory and anti-doping status of these compounds?

Neither BPC-157 nor thymosin beta-4 is an approved drug product under the Federal Food, Drug, and Cosmetic Act, and neither is a controlled substance under the Controlled Substances Act, so neither carries a DEA schedule. BPC-157 was evaluated by the FDA within its bulk drug substances review for compounding and was placed in the category reserved for substances raising significant safety concerns, which effectively closed the compounding route under section 503A. That classification is a regulatory finding about compounding eligibility, not a statement that research with the compound is prohibited.

Anti-doping status is separate and stricter. The World Anti-Doping Agency prohibits thymosin beta-4 and its derivatives, naming TB-500 explicitly within its growth factor section, and BPC-157 falls under the category covering substances with no current approval for human therapeutic use. Both are therefore prohibited at all times in tested sport, a point covered in context in a discussion of how professional leagues have treated BPC-157. Cross border movement of research material raises a distinct set of questions, addressed separately in an overview of transport and customs considerations for BPC-157. Organisational details for the supplier, including operating information, are listed on the Real Peptides company information page.

This page is general information, not legal advice; consult a qualified attorney for advice on any specific situation.

How was this page researched?

This page was compiled from PubMed indexed primary research and review articles only, listed in full in the references below. Mechanistic statements are attributed to the specific paper reporting them, and claims without an identifiable indexed source are described qualitatively rather than quantified. Molecular weights, sequences and CAS registry numbers were checked against chemical registry entries rather than against supplier listings. No first party experimental data, customer reports or unpublished observations were used. Where the literature is silent, such as on controlled combination studies of the two compounds, the page states that silence rather than filling it with inference.

Further reading on adjacent research questions includes published discussion of reported sleep related observations in the BPC-157 literature, whether any evidence links BPC-157 to hormonal tissue effects, what models exist on BPC-157 alongside non steroidal anti inflammatory compounds, research questions raised about BPC-157 and antibiotic compounds, whether growth hormone and BPC-157 have been examined in the same studies, and what is known about BPC-157 alongside incretin research compounds.

The real lesson of the BPC 157 TB 500 literature is that the weakest link is rarely the science. The rodent data is specific, repeatable and well described. What fails is everything downstream of it: a trade name that does not specify a molecule, a certificate written by the party selling the vial, and a synergy claim that no experiment has tested. A research program that fixes those three things before it begins will produce an interpretable result whichever way the data falls, and one that does not will produce a number nobody can defend.

References

• Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011. PMID: 21548867
• Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell migration and cell proliferation. J Appl Physiol. 2011. PMID: 21030672
• Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. PMID: 25415472
• Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. PMID: 30915550
• Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021. PMID: 34267654
• Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. PMID: 22074294
• Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. J Invest

References

Peer-reviewed sources on BPC-157 indexed in PubMed, listed for research context. Real Peptides supplies BPC-157 for laboratory research use only.

1. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949. doi:10.1177/15563316251355551
2. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999. doi:10.3390/ph18020185
3. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine, 2025. PMID 40789979. doi:10.1007/s12178-025-09990-7
4. Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel, Switzerland), 2024. PMID 39204186. doi:10.3390/ph17081081
5. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences, 2026. PMID 41898733. doi:10.3390/ijms27062876
6. BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International journal of molecular sciences, 2026. PMID 42278509. doi:10.3390/ijms27114984
7. Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Scientific reports, 2026. PMID 42204242. doi:10.1038/s41598-026-55449-1
8. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026. PMID 42542926. doi:10.52312/jdrs.2026.2951